206 related articles for article (PubMed ID: 17911178)
1. Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency.
Dawson-Hughes B; Chen P; Krege JH
J Clin Endocrinol Metab; 2007 Dec; 92(12):4630-6. PubMed ID: 17911178
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.
Miller PD; Schwartz EN; Chen P; Misurski DA; Krege JH
Osteoporos Int; 2007 Jan; 18(1):59-68. PubMed ID: 17013567
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
4. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
5. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
[TBL] [Abstract][Full Text] [Related]
6. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
7. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
8. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
Anastasilakis AD; Polyzos SA; Avramidis A; Toulis KA; Papatheodorou A; Terpos E
Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
[TBL] [Abstract][Full Text] [Related]
9. Consumption of yogurts fortified in vitamin D and calcium reduces serum parathyroid hormone and markers of bone resorption: a double-blind randomized controlled trial in institutionalized elderly women.
Bonjour JP; Benoit V; Payen F; Kraenzlin M
J Clin Endocrinol Metab; 2013 Jul; 98(7):2915-21. PubMed ID: 23653431
[TBL] [Abstract][Full Text] [Related]
10. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment.
Watts NB; Miller PD; Kohlmeier LA; Sebba A; Chen P; Wong M; Krohn K
J Bone Miner Res; 2009 Jun; 24(6):1125-31. PubMed ID: 19113918
[TBL] [Abstract][Full Text] [Related]
11. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.
Krege JH; Wan X
Bone; 2012 Jan; 50(1):161-4. PubMed ID: 22036910
[TBL] [Abstract][Full Text] [Related]
12. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
[TBL] [Abstract][Full Text] [Related]
13. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
Marcus R; Wang O; Satterwhite J; Mitlak B
J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
[TBL] [Abstract][Full Text] [Related]
14. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
15. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide.
Miller PD; Bilezikian JP; Diaz-Curiel M; Chen P; Marin F; Krege JH; Wong M; Marcus R
J Clin Endocrinol Metab; 2007 Sep; 92(9):3535-41. PubMed ID: 17609307
[TBL] [Abstract][Full Text] [Related]
16. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women.
Cosman F; Lane NE; Bolognese MA; Zanchetta JR; Garcia-Hernandez PA; Sees K; Matriano JA; Gaumer K; Daddona PE
J Clin Endocrinol Metab; 2010 Jan; 95(1):151-8. PubMed ID: 19858319
[TBL] [Abstract][Full Text] [Related]
17. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.
Dempster DW; Zhou H; Recker RR; Brown JP; Bolognese MA; Recknor CP; Kendler DL; Lewiecki EM; Hanley DA; Rao DS; Miller PD; Woodson GC; Lindsay R; Binkley N; Wan X; Ruff VA; Janos B; Taylor KA
J Clin Endocrinol Metab; 2012 Aug; 97(8):2799-808. PubMed ID: 22701017
[TBL] [Abstract][Full Text] [Related]
18. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
Black DM; Schwartz AV; Ensrud KE; Cauley JA; Levis S; Quandt SA; Satterfield S; Wallace RB; Bauer DC; Palermo L; Wehren LE; Lombardi A; Santora AC; Cummings SR;
JAMA; 2006 Dec; 296(24):2927-38. PubMed ID: 17190893
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
20. Short-term effects on bone turnover markers of a single high dose of oral vitamin D₃.
Rossini M; Gatti D; Viapiana O; Fracassi E; Idolazzi L; Zanoni S; Adami S
J Clin Endocrinol Metab; 2012 Apr; 97(4):E622-6. PubMed ID: 22298802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
